Acorda prices public offer at $21.50

Of the shares being sold, 3.22 million shares are being sold by the company and 83,000 shares are being sold by a selling stockholder. The company has granted the underwriters a 30-day option to purchase up to an additional 495,000 shares of common stock at the public offering price.

The company intends to use the net proceeds from this offering to complete its second Phase III Fampridine-SR clinical trial in multiple sclerosis and to conduct other activities related to the filing of a new drug application and preparation for potential market launch of Fampridine-SR (if approved), for R&D and for general corporate purposes.